{"id":8246,"date":"2024-03-04T23:06:17","date_gmt":"2024-03-04T15:06:17","guid":{"rendered":"https:\/\/flcube.com\/?p=8246"},"modified":"2024-10-20T23:08:09","modified_gmt":"2024-10-20T15:08:09","slug":"alzecure-pharmas-alzheimers-drug-candidate-acd856-receives-global-patent-awards","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=8246","title":{"rendered":"AlzeCure Pharma\u2019s Alzheimer\u2019s Drug Candidate ACD856 Receives Global Patent Awards"},"content":{"rendered":"\n

AlzeCure Pharma, a Swedish pharmaceutical company, has announced the receipt of patent approval awards for its clinical drug candidate ACD856 in several countries, including China. The drug, which holds potential as a treatment for Alzheimer\u2019s disease and other cognitive impairment-related disorders, has been granted protection until 2039 in China, India, South Africa, Israel, Hong Kong, and Mexico. These recent awards complement earlier patent approvals covering the United States and the European Union.<\/p>\n\n\n\n

ACD856, developed on AlzeCure\u2019s NeuroRestore platform, is designed to stimulate neurotrophic signaling pathways, thereby enhancing nerve cell function and improving memory. The drug’s active ingredients target BDNF (Brain Derived Neurotrophic Factor) and NGF (Nerve Growth Factor). ACD856 completed a Phase I clinical trial in 2022, demonstrating good safety and tolerability in humans and showing an ability to cross the blood-brain barrier to activate regions of the brain central to cognition and depression treatment. New preclinical results indicate potential neuroprotective and disease-modifying effects with these substances. AlzeCure has expressed openness to licensing and\/or partnership deals regarding the global development of its drug candidate.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

AlzeCure Pharma, a Swedish pharmaceutical company, has announced the receipt of patent approval awards for…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[61],"tags":[1446],"class_list":["post-8246","post","type-post","status-publish","format-standard","hentry","category-legal-ip","tag-alzecure-pharma"],"yoast_head":"\nAlzeCure Pharma\u2019s Alzheimer\u2019s Drug Candidate ACD856 Receives Global Patent Awards - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AlzeCure Pharma, a Swedish pharmaceutical company, has announced the receipt of patent approval awards for its clinical drug candidate ACD856 in several countries, including China. The drug, which holds potential as a treatment for Alzheimer\u2019s disease and other cognitive impairment-related disorders, has been granted protection until 2039 in China, India, South Africa, Israel, Hong Kong, and Mexico. These recent awards complement earlier patent approvals covering the United States and the European Union.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=8246\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AlzeCure Pharma\u2019s Alzheimer\u2019s Drug Candidate ACD856 Receives Global Patent Awards\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=8246\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-04T15:06:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-20T15:08:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8246#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8246\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AlzeCure Pharma\u2019s Alzheimer\u2019s Drug Candidate ACD856 Receives Global Patent Awards\",\"datePublished\":\"2024-03-04T15:06:17+00:00\",\"dateModified\":\"2024-10-20T15:08:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8246\"},\"wordCount\":191,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AlzeCure Pharma\"],\"articleSection\":[\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8246#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8246\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=8246\",\"name\":\"AlzeCure Pharma\u2019s Alzheimer\u2019s Drug Candidate ACD856 Receives Global Patent Awards - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-03-04T15:06:17+00:00\",\"dateModified\":\"2024-10-20T15:08:09+00:00\",\"description\":\"AlzeCure Pharma, a Swedish pharmaceutical company, has announced the receipt of patent approval awards for its clinical drug candidate ACD856 in several countries, including China. The drug, which holds potential as a treatment for Alzheimer\u2019s disease and other cognitive impairment-related disorders, has been granted protection until 2039 in China, India, South Africa, Israel, Hong Kong, and Mexico. These recent awards complement earlier patent approvals covering the United States and the European Union.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8246#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=8246\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=8246#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AlzeCure Pharma\u2019s Alzheimer\u2019s Drug Candidate ACD856 Receives Global Patent Awards\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AlzeCure Pharma\u2019s Alzheimer\u2019s Drug Candidate ACD856 Receives Global Patent Awards - Insight, China's Pharmaceutical Industry","description":"AlzeCure Pharma, a Swedish pharmaceutical company, has announced the receipt of patent approval awards for its clinical drug candidate ACD856 in several countries, including China. The drug, which holds potential as a treatment for Alzheimer\u2019s disease and other cognitive impairment-related disorders, has been granted protection until 2039 in China, India, South Africa, Israel, Hong Kong, and Mexico. These recent awards complement earlier patent approvals covering the United States and the European Union.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=8246","og_locale":"en_US","og_type":"article","og_title":"AlzeCure Pharma\u2019s Alzheimer\u2019s Drug Candidate ACD856 Receives Global Patent Awards","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=8246","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-03-04T15:06:17+00:00","article_modified_time":"2024-10-20T15:08:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=8246#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=8246"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AlzeCure Pharma\u2019s Alzheimer\u2019s Drug Candidate ACD856 Receives Global Patent Awards","datePublished":"2024-03-04T15:06:17+00:00","dateModified":"2024-10-20T15:08:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=8246"},"wordCount":191,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AlzeCure Pharma"],"articleSection":["Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=8246#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=8246","url":"https:\/\/flcube.com\/?p=8246","name":"AlzeCure Pharma\u2019s Alzheimer\u2019s Drug Candidate ACD856 Receives Global Patent Awards - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-03-04T15:06:17+00:00","dateModified":"2024-10-20T15:08:09+00:00","description":"AlzeCure Pharma, a Swedish pharmaceutical company, has announced the receipt of patent approval awards for its clinical drug candidate ACD856 in several countries, including China. The drug, which holds potential as a treatment for Alzheimer\u2019s disease and other cognitive impairment-related disorders, has been granted protection until 2039 in China, India, South Africa, Israel, Hong Kong, and Mexico. These recent awards complement earlier patent approvals covering the United States and the European Union.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=8246#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=8246"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=8246#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AlzeCure Pharma\u2019s Alzheimer\u2019s Drug Candidate ACD856 Receives Global Patent Awards"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8246"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8246\/revisions"}],"predecessor-version":[{"id":8247,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/8246\/revisions\/8247"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}